What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Richard Conway RichardPAConway
3 years 6 months ago
Montastruc et al. VigiBase study of CV and VTE events in JAKi vs TNFi. >270000 events. DECREASE in MACE ROR=0.87 [95%CI 0.80-0.95]. INCREASE in DVT: ROR=3.99 [3.15-5.04], PE: ROR=3.47 [2.90-4.13] @RheumNow #EULAR2022 OP0268 https://t.co/lUin7ciXWt https://t.co/Gr4Kvd8F7R
Aurelie Najm AurelieRheumo
3 years 6 months ago
Survival of RA-ILD pts w/ lung 🫁 transplantation
Retrospective single centre study
*Mortality 36%
*Usual Interstitial Pneumonia worst prognosis w/ HR 7.13 (did not reach significance, small cohort)
*Survival time comparable to other lung Tx cohorts
#EULAR2022 OP0275 @RheumNow https://t.co/LslPxyXJCp
TheDaoIndex KDAO2011
3 years 6 months ago
OP0285 Voclosoporin effective in #lupusNephritis from AURA-LV and AURORA1 to achieve EULAR/ERA nephritis targets (proteinuria < 0.7 mg/mg and pred < 7.5 mg/d) at 1 year @AuriniaPharma #EULAR2022 @rheumnow https://t.co/0GoCgP98F2
David Liew drdavidliew
3 years 6 months ago
MACE in JAKi vs TNFi: did spontaneous reporting pharmacovigilance pick it?
Vigibase: MACE (really MI) & VTE signals there before the scare
Always chance regulatory warnings cause stimulated reporting
but signal here was clear before RCT-driven alerts
OP0268 #EULAR2022 @RheumNow https://t.co/hTJD1gMgyy
Dr. John Cush RheumNow
3 years 6 months ago
Video: Further Considerations of the ORAL Surveillance Study
Further Considerations of ORAL Surveillance Study - this week there are new analyses and sub-analyses that further explain findings and who this data applies to. #EULAR2022
https://t.co/a2XKthtMbs https://t.co/kYNS1AesHT
Dr. Antoni Chan synovialjoints
3 years 6 months ago
Real world study of over 6500 patients from a French Health Insurance database by Pina Vegas et al showed higher persistence of IL17i than TNFi for PsA and PsO. IL17i had better persistence than IL12/23 for PsA and no difference for PsO over 3 years #EULAR2022 @RheumNow POS0075 https://t.co/hBI8tgb5Jb
Dr. John Cush RheumNow
3 years 6 months ago
WATCH: New 2022 ASAS/EULAR Recommendations on the Management of AxSpA
Dr. Sophia Ramiro (Leiden University Medical Center) presents an overview of the new Spondyloarthritis treatment guidelines from ASAS/EULAR Task Force. #EULAR2022
https://t.co/AiCNQPm6KB https://t.co/kn4rmcbZrH
A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, fibromyalgia, back pain, sarcopenia, APS, IgG4 and imaging in vasculitis.
Dr. Rachel Tate uptoTate
3 years 6 months ago
What is "backfill" on MRI? Answer: joint space lesions with a calcified matrix resembling new bone formation found in axSpA. #EULAR2022 POS0149 argues for a standardization of this nomenclature. @RheumNow https://t.co/ifrowQnRcn
Dr. Rachel Tate uptoTate
3 years 6 months ago
To contrast or not to contrast (in RA hand MRI?) POS0718 from #EULAR2022 showed good correlation between contrast/non-contrast imaging in synovitis, less so in tenosynovitis however. https://t.co/xL4XcRlIog
@RheumNow https://t.co/0cTep6MHLu
Dr. Antoni Chan synovialjoints
3 years 6 months ago
The expanding spectrum of Systemic Autoinflammatory Disease (SAID) by Marco Gattorno using a combination of clinical assessment, genetic testing and imaging to define the phenotype of SAID #EULAR2022 @RheumNow https://t.co/TGYmfExHxD
EULAR Congress 2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years. I wanted to share with you the ones that caught my eye because they can potentially impact medical practice.
Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research (abstract OP0015) presented on the first day of EULAR 2022 in Copenhagen.
Poster Hall